Literature DB >> 10146894

Clinical and economic factors in the selection of low-osmolality contrast media.

W H Matthai1.   

Abstract

Both high- and low-osmolality contrast media are available for most radiographic procedures requiring iodinated contrast material. Newer low-osmolality contrast media cost much more than conventional high-osmolality formulations but cause fewer adverse reactions. However, most of these reactions are mild and easily treated, and do not affect the outcome of the procedure. Whether these additional clinical benefits justify the added cost is a crucial question which has not been answered. This review introduces some of the economic and clinical issues on which the choice of contrast media should be based. Low-osmolality contrast agents are not cost effective considering current pricing strategies and current inability to select patients at increased risk of an adverse event. Therefore, a better understanding of these adverse events and their mechanism takes on added importance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 10146894     DOI: 10.2165/00019053-199405030-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  52 in total

1.  EFFECT OF CONCENTRATED CONTRAST MEDIA DURING ANGIOGRAPHY ON PLASMA VOLUME AND PLASMA OSMOLALITY.

Authors:  L T ISERI; M A KAPLAN; M J EVANS; E D NICKEL
Journal:  Am Heart J       Date:  1965-02       Impact factor: 4.749

Review 2.  Choice of contrast agents for cardiac angiography: review and recommendations based on clinically important distinctions.

Authors:  W H Matthai; J W Hirshfeld
Journal:  Cathet Cardiovasc Diagn       Date:  1991-04

3.  Hemodynamic and electrocardiographic effects of ioversol during cardiac angiography. Comparison with iopamidol and diatrizoate.

Authors:  J W Hirshfeld; J Wieland; C A Davis; B D Giles; D Passione; M B Ray; N S Ripley
Journal:  Invest Radiol       Date:  1989-02       Impact factor: 6.016

Review 4.  Comparative safety of high-osmolality and low-osmolality radiographic contrast agents. Report of a multidisciplinary working group.

Authors:  V Lawrence; W Matthai; S Hartmaier
Journal:  Invest Radiol       Date:  1992-01       Impact factor: 6.016

5.  Clinical superiority of a new nonionic contrast agent (iopamidol) for cardiac angiography.

Authors:  E W Gertz; J A Wisneski; D Chiu; J R Akin; C Hu
Journal:  J Am Coll Cardiol       Date:  1985-02       Impact factor: 24.094

6.  Net costs from three perspectives of using low versus high osmolality contrast medium in diagnostic angiocardiography.

Authors:  N R Powe; A J Davidoff; R D Moore; J A Brinker; G F Anderson; M R Litt; R Gopalan; S L Graziano; E P Steinberg
Journal:  J Am Coll Cardiol       Date:  1993-06       Impact factor: 24.094

7.  Mortality during excretory urography: Mayo Clinic experience.

Authors:  G W Hartman; R R Hattery; D M Witten; B Williamson
Journal:  AJR Am J Roentgenol       Date:  1982-11       Impact factor: 3.959

8.  Contrast venography of the leg: diagnostic efficacy, tolerance, and complication rates with ionic and nonionic contrast media.

Authors:  M A Bettmann; A Robbins; S D Braun; S Wetzner; N R Dunnick; J Finkelstein
Journal:  Radiology       Date:  1987-10       Impact factor: 11.105

9.  Contrast medium-induced adverse reactions: economic outcome.

Authors:  N R Powe; E P Steinberg; J E Erickson; R D Moore; C R Smith; R I White; J A Brinker; E K Fishman; S J Zinreich; M L Kinnison
Journal:  Radiology       Date:  1988-10       Impact factor: 11.105

10.  Safety and cost effectiveness of high-osmolality as compared with low-osmolality contrast material in patients undergoing cardiac angiography.

Authors:  E P Steinberg; R D Moore; N R Powe; R Gopalan; A J Davidoff; M Litt; S Graziano; J A Brinker
Journal:  N Engl J Med       Date:  1992-02-13       Impact factor: 91.245

View more
  1 in total

Review 1.  Iomeprol: a review of its use as a contrast medium.

Authors:  M Dooley; B Jarvis
Journal:  Drugs       Date:  2000-05       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.